#South Korea #Yongin #RSV #GCCL #WVC 2026

GCCL Showcases RSV FRNT Research and Bioanalytical Capabilities at World Vaccine Congress 2026

GCCL Co., Ltd., a prominent provider of clinical trial laboratory services, is set to make a significant impact at the upcoming World Vaccine Congress 2026 (WVC 2026) held in Washington, D.C., from March 30 to April 2, 2026. At this prestigious event, GCCL will showcase its latest advancements through an exhibition booth and a poster presentation detailing innovative research developments.

One of the highlights of GCCL's presentation is the Focus Reduction Neutralization Test (FRNT) assay, designed specifically for assessing neutralizing antibody titers against the Respiratory Syncytial Virus (RSV). This critical research, led by Dr. Jaewook Hyeon and his dedicated team, aims to enhance the efficiency of conventional neutralizing antibody assays. The newly established automated platform streamlines detection processes by leveraging instruments to capture and analyze infection signals automatically.

The performance of this novel assay was validated against the WHO International Standard and through its application to the licensed monoclonal antibody therapy palivizumab (Synagis®). By implementing an automated FRNT analytical platform, GCCL is set to facilitate key phases in the development of RSV vaccines and therapies, including candidate screening, efficacy evaluations, and clinical immunogenicity assessments.

As global reliance on a limited number of specialized contract research organizations (CROs) continues, GCCL's aim is to enhance accessibility to high-quality neutralizing antibody testing for vaccine and therapeutic developers. This capability promises to provide clients with more dependable immunogenicity assessment data, aiding in the optimization of development timelines.

In addition to the poster presentation, GCCL will operate an exhibition booth that highlights the company's integrated capabilities in clinical trial sample analysis and assay development specifically for vaccine and therapeutic development. The team will actively engage potential partners, seeking collaborative business opportunities with international vaccine and pharmaceutical companies attending WVC 2026.

Kwan Goo Cho, CEO of GCCL, expressed the company's commitment by stating, "Leveraging the analytical capabilities required throughout vaccine and therapeutic development, GCCL will continue expanding discussions with global partners on joint projects and service collaborations, with the goal of translating these opportunities into tangible business outcomes. Through our exhibition booth and poster presentation, we will further refine our ability to address the analytical needs of global clients and strengthen the foundation for long-term partnerships as a trusted lab partner for vaccine and therapeutic development worldwide."

The World Vaccine Congress is a vital gathering for industry leaders in vaccine research and development, and GCCL's participation reflects its dedication to pioneering advancements in clinical laboratory services. Attendees can look forward to valuable insights into the future of vaccine development, particularly concerning RSV, through GCCL’s innovative solutions and collaborative approach. This event not only signifies GCCL's growth in the sector but also represents a commitment to improving public health outcomes through scientific research and partnerships.